Continuum Advisory’s AIM ImmunoTech AIM Stock Holding History

Continuum Advisory’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142	Buy	+500	New	+$228	﹤0.01%	1963

Other funds holding AIM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Continuum Advisory's AIM Position: Q2 2026 in Review

Continuum Advisory opened a new position in AIM ImmunoTech (AIM) in Q2 2026: 500 shares worth $142. The stake represents ﹤0.01% of the portfolio and ranks #1963 among its holdings.

18 funds tracked by Wall St. Rank hold AIM as of Q2 2026.

Continuum Advisory held 500 shares of AIM ImmunoTech worth $142 as of Q2 2026.
AIM ImmunoTech was a new Continuum Advisory position in Q2 2026.
AIM ImmunoTech made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1963 holding.
18 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.